肝癌治疗药物市场规模、份额、成长分析，按药物、类型、分销管道、地区划分 - 按行业预测，2024-2031

2022年全球肝癌药物市场规模为29.8亿美元，从2023年的35.1亿美元成长到2031年的131.2亿美元，预计在预测期间（2024年-2031年）将以年复合成长率为 17.9%。

肝癌治疗领域的市场成长是由新药供应量的增加、产品线的强大和公众意识的提高所推动的。肝癌发生率的上升进一步推动了这种成长，尤其是在生活方式不健康的老年人中。肝细胞癌（HCC）占原发性肝癌的 75-90%。许多危险因素，例如肝炎感染和肝硬化，都是可以改变的，这为改变生活方式和接种肝炎疫苗等预防策略提供了机会。从地理来看，北美和南欧的肝癌死亡率最高，而东亚的男性（每10万人中有31.9人）和女性（每10万人中有10.2人）发病率最高。这凸显了需要有针对性的介入和治疗的重要领域。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特分析与影响
  • 竞争公司之间的敌对关係
  • 替代品的威胁
  • 买方议价能力
  • 新进入者的威胁
  • 供应商的议价能力

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步
• 监管环境
• 案例研究

肝癌治疗药物市场规模：依药物分类

• 市场概况
• 标靶治疗
• 免疫疗法
• 化疗

肝癌治疗药物市场规模：依类型

• 市场概况
• 肝细胞癌
• 胆管癌
• 肝母细胞瘤
• 其他的

肝癌治疗药物市场规模：依通路划分

• 市场概况
• 医院药房
• 零售药房
• 网路药房

肝癌治疗药物市场规模：依地区划分

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Exelixis, Inc.
• Merck KGaA
• Bristol-Myers Squibb Company
• Bayer AG
• Thermo Fisher Scientific Inc.
• Pfizer Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Abbott Laboratories
• Gilead Sciences
• Zydus Pharmaceuticals Inc
• AbbVie Inc.
• Johnson & Johnson Services Inc.

结论和建议

Global Liver Cancer Drugs Market size was valued at USD 2.98 billion in 2022 and is poised to grow from USD 3.51 billion in 2023 to USD 13.12 billion by 2031, growing at a CAGR of 17.9% during the forecast period (2024-2031).

Market growth in the liver cancer treatment sector is driven by increased availability of novel drugs, robust pipelines, and heightened public awareness. The rising incidence of liver cancer, particularly among the aging population with unhealthful lifestyles, is further propelling this growth. Hepatocellular carcinomas (HCCs) represent 75-90% of primary liver cancer cases. Many risk factors, such as hepatitis infection and cirrhosis, are modifiable, presenting opportunities for preventive strategies like lifestyle changes and hepatitis vaccination. Geographically, North America and Southern Europe experience the highest mortality rates for liver cancer, while Eastern Asia shows the most significant incidence rates for males (31.9 per 100,000) and females (10.2 per 100,000). This highlights critical areas for targeted interventions and treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cancer Drugs Market Segmental Analysis

Global Liver Cancer Drugs Market is segmented by Drug, Type, Distribution Chanel, and region. Based on Drug, the market is segmented into Targeted Therapy, Immunotherapy, and Chemotherapy. Based on Type, the market is segmented into Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, and Others. Based on Distribution Chanel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cancer Drugs Market

The global market for liver cancer drugs is driven by the alarming rise in liver cancer cases, which sees around one million new diagnoses annually worldwide. The increasing number of smokers and alcohol consumers, alongside urbanization, significantly contributes to liver-related health issues. Government initiatives and investments from global healthcare organizations further bolster the growth of this market. Moreover, the emergence of innovative liver cancer medications and a rise in FDA approvals specifically targeting hepatocellular carcinoma-which represents nearly 90% of liver cancer cases-reflects heightened research and development efforts to combat this critical disease, indicating a promising future for the industry.

Restraints in the Global Liver Cancer Drugs Market

The Global Liver Cancer Drugs market faces significant constraints that could impede its growth trajectory. Key among these are stringent regulatory requirements imposed by governments, which may hamper the approval process for numerous small molecules and biologics in developed nations. As a result, products that are not equipped with cutting-edge technology may encounter elevated rates of processing errors, compromised quality, and heightened cost challenges. These factors collectively pose obstacles for market expansion, potentially leading to reduced access and limited options for patients and healthcare providers. Consequently, the overall potential for growth within this therapeutic market may be significantly affected.

Market Trends of the Global Liver Cancer Drugs Market

The Global Liver Cancer Drugs market is experiencing a significant upward trend, largely driven by robust research and development initiatives aimed at enhancing treatment outcomes. With an emphasis on prolonging patient survival and improving quality of life, pharmaceutical companies are increasingly focusing on innovative approaches such as immunotherapy and targeted therapies. Collaborative efforts, exemplified by partnerships like that between Sirnaomics and Innovent Biologics for clinical research on Tyvy and STP705, are accelerating advancements in liver cancer treatment. This strategic alliance and others like it are not only propelling clinical progress but also expanding the market's potential, thereby positioning the sector for sustained growth and investment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Liver Cancer Drugs Market Size by Drug & CAGR (2024-2031)

• Market Overview
• Targeted Therapy
• Immunotherapy
• Chemotherapy

Global Liver Cancer Drugs Market Size by Type & CAGR (2024-2031)

• Market Overview
• Hepatocellular Carcinoma
• Cholangio Carcinoma
• Hepatoblastoma
• Others

Global Liver Cancer Drugs Market Size by Distribution Chanel & CAGR (2024-2031)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Liver Cancer Drugs Market Size & CAGR (2024-2031)

• North America (Drug, Type, Distribution Chanel)
  • US
  • Canada
• Europe (Drug, Type, Distribution Chanel)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Drug, Type, Distribution Chanel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Drug, Type, Distribution Chanel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug, Type, Distribution Chanel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation